[
    [
        {
            "time": "2023-03-15",
            "original_text": "中国银河给予贝达药业推荐评级，埃克替尼继续快速放量，恩沙替尼获批打破单药困局",
            "features": {
                "keywords": [
                    "贝达药业",
                    "推荐评级",
                    "埃克替尼",
                    "恩沙替尼",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国银河给予贝达药业推荐评级，埃克替尼继续快速放量，恩沙替尼获批打破单药困局",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-16",
            "original_text": "医药行业周报：本周医药涨幅居前 建议关注核心资产触底反弹",
            "features": {
                "keywords": [
                    "医药行业",
                    "涨幅",
                    "核心资产",
                    "触底反弹"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：本周医药涨幅居前 建议关注核心资产触底反弹",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-17",
            "original_text": "华鑫证券维持贝达药业推荐评级：业绩符合预期，多个产品进入收获期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "推荐评级",
                    "业绩",
                    "收获期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华鑫证券维持贝达药业推荐评级：业绩符合预期，多个产品进入收获期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-18",
            "original_text": "西部证券维持贝达药业买入评级：埃克替尼持续放量，研发管线迎来收获期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "买入评级",
                    "埃克替尼",
                    "研发管线",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券维持贝达药业买入评级：埃克替尼持续放量，研发管线迎来收获期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-19",
            "original_text": "贝达药业盈利狂飙背后：研发投入占比惊人维持在40%左右",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盈利",
                    "研发投入",
                    "40%"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业盈利狂飙背后：研发投入占比惊人维持在40%左右",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-20",
            "original_text": "卡瑞利珠单抗2项新适应证报上市；艾力斯艾弗沙患者援助项目启动；贝达药业、赛生药业、先声药业2020年业绩报告",
            "features": {
                "keywords": [
                    "卡瑞利珠单抗",
                    "适应证",
                    "艾力斯",
                    "艾弗沙",
                    "贝达药业",
                    "赛生药业",
                    "先声药业",
                    "业绩报告"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "卡瑞利珠单抗2项新适应证报上市；艾力斯艾弗沙患者援助项目启动；贝达药业、赛生药业、先声药业2020年业绩报告",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "华西证券维持贝达药业买入评级：业绩符合预期，后期管线快速推进",
            "features": {
                "keywords": [
                    "贝达药业",
                    "买入评级",
                    "业绩",
                    "后期管线",
                    "快速推进"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华西证券维持贝达药业买入评级：业绩符合预期，后期管线快速推进",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]